Can a Three-Drug cocktail replace chemo for follicular lymphoma?
NCT ID NCT07719855
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a combination of three targeted drugs—orelabrutinib, obinutuzumab, and lenalidomide—can work as well as or better than standard chemotherapy for people with previously untreated follicular lymphoma. The goal is to see if this chemo-free approach can control the cancer while causing fewer side effects. The study enrolls adults with grade 1-3A follicular lymphoma who have not received prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of orelabrutinib, obinutuzumab, and lenalidomide
- What this could lead to
- If successful, this drug combination could offer a chemotherapy-free option for follicular lymphoma, potentially improving outcomes and quality of life.
- What could go wrong
- This is an early-phase trial, and the combination may cause unexpected side effects or fail to outperform standard chemotherapy. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hosiptal
Shanghai, Shanghai Municipality, 20025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to outsmart recurring lymphoma
- New combo pill attack aims to control blood cancers
- Smart blood pressure cuffs could protect cancer patients from heart risks
- New cell therapy CT1182 takes on tough lymphoma
- New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial
- Chemo-free triplet aims to outsmart incurable lymphoma